High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

Journal of Clinical Oncology

Volumn 23, Issue 28, 2005, Pages 7013-7023

  Romaguera, Jorge E ^a   Fayad, Luis ^a   Rodriguez, Maria A ^a   Broglio, Kristine R ^a   Hagemeister, Frederick B ^a   Pro, Barbara ^a   McLaughlin, Peter ^a   Younes, Anas ^a   Samaniego, Felipe ^a   Goy, Andre ^a   Sarris, Andreas H ^a   Dang, Nam H ^a   Wang, Michael ^a   Beasley, Virginia ^a   Jeffrey Medeiros, L ^a   Katz, Ruth L ^a   Gagneja, Harish ^a   Samuels, Barry I ^a   Smith, Terry L ^a   Cabanillas, Fernando F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; FLUCONAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; MESNA; METHOTREXATE; RITUXIMAB; VALACICLOVIR; VINCRISTINE; ANTINEOPLASTIC AGENT; CVAD PROTOCOL; MONOCLONAL ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BACTEREMIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASIA; NEUTROPENIA; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; STAPHYLOCOCCUS INFECTION; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; AGE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; TREATMENT OUTCOME; VINCRISTINE;

EID: 27244452464     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.1825     Document Type: Article

References (35)

1. Harris NL, Jaffe ES, Diebold J, et al: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Arlie House, Virginia, November 1997. Histopathology 36:69-86, 2000
2. Majlis A, Pugh W, Rodriguez MA, et al: Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants. J Clin Oncol 15:1664-1671, 1997
3. Meusers P, Engelhard M, Bartels H, et al: Multicenter randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis. Hematol Oncol 7:365-380, 1989
4. Norton AJ, Mathews J, Pappa V, et al: Mantle cell lymphoma: Natural history defined in a serially biopsied population over a 20 year period. Ann Oncol 6:249-256, 1995
5. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
6. Teodorovic I, Pittaluga S, Kluinnelemans JC: Efficacy of four different regimens in 64 mantle cell lymphoma cases: Clinico-pathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. J Clin Oncol 13:2819-2826, 1995
7. Zucca E, Roggero E, Pinotti G, et al: Patterns of survival in mantle cell lymphomas. Ann Oncol 6:257-282, 1995
8. Fisher RI, Dahlberg S, Nathwani BN, et al: A clinical analysis of two indolent lymphoma entities: Mantle cell lymphoma and marginal zone lymphoma (including mucosa-associated lymphoid tissue and monocytoid B-cell categories): A Southwest Oncology Group study. Blood 85:1075-1084, 1995
9. Greiner TC, Moynihan MJ, Chan WC, et al: P53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996
10. Foran JM, Rohatiner AZ, Cunningham D, et al: European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 18:317-324, 2000
11. Howard OM, Gribben JG, Neuberg DS, et al: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival. J Clin Oncol 20:1288-1294, 2002
12. Khouri IF, Romaguera J, Kantarjian H, et al: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem cell transplantation: An active regimen for aggressive mantle cell lymphoma. J Clin Oncol 16:3803-3809, 1998
13. Stanley KE: Prognostic factors for survival in patients with inoperative lung cancer. J Natl Cancer Inst 65:25-32, 1980
14. Luthra R, Sarris AH, Hai S, et al: Real-time 5′ → 3′ exonuclease-based PCR assay for the detection of the t(11;13)(q13;q32). Am J Clin Pathol 112:254-530, 1999
15. Katz RI, Caraway NP, Gu J, et al: Detection of chromosome 11q13 breakpoints by interphase fluorescence in situ hybridization: A useful ancillary method for the diagnosis of mantle cell lymphoma. Am J Clin Pathol 114:248-257, 2000
16. Cheson BD, Horning SJ, Coiffier B, et al: Report on an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Peto R, Peto J: Asymptotically efficient rank invariant test procedures. J R Stat Soc 35:185-207, 1972
19. A predictive model for aggressive non-Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
20. Barista I, Romaguera JE, Cabanillas F: Mantle cell lymphoma. Lancet Oncol 2:141-148, 2001
21. Wilson W, Neelapu S, Rosenwald A, et al: ldiotype vaccine and dose-adjusted EPOCH-rituximab treatment in untreated mantle-cell lymphoma: Preliminary report on clinical outcome and analysis of immune response. Blood 102:11, 2003 (abstr 358)
22. Hiddeman W, Unterhalt M, Dreyling M, et al: The addition of rituximab to combination chemotherapy (CT) significantly improves the treatment of mantle cell lymphomas (MCL): Results of two prospective randomized studies by the German Low Grade Lymphoma Study Group (GLSG). Blood 100:92a, 2002 (suppl 1, abstr 339)
23. Levine AM, Espina BM, Mohrbacher LH, et al: Fludarabine, mitoxantrone, and Rituxan: An effective regimen for the treatment of mantle cell lymphoma. Blood 100:361 a, 2002 (suppl 1. abstr 1399)
24. Kahl BS, McGovern J, Blank J, et al: Phase Il study of modified hyper-CVAD with rituximab maintenance for previously untreated mantle cell lymphoma: A Wisconsin Oncology Network Study. Blood 104:11, 2004 (abstr 1388)
25. Zelenetz AD, Donnelly G, Halaas J, et al: Initial treatment of mantle cell lymphoma with sequential radioimmunotherapy with tositumomab/iodine I131 (I-tositumomab) followed by CHOP chemotherapy results in a high complete remission rate. Blood 102:11, 2003 (abstr 1477)
26. Gianni AM, Magni M, Martelli M, et al: Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 102:749-755, 2003
27. Khouri IF, Saliba RM, Okoroji GJ, et al: Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: The prognostic value of beta2-microglobulin and the tumor score. Cancer 98:2630-2635, 2003
28. Vandenberghe E, Ruiz de Elvire C, Loberiza FR, et al: Outcome of autologous transplantation for mantle cell lymphoma: A study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 120:793-800, 2003
29. Andersen NS, Pedersen L, Elonen E, et al: Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: Outcome related to remission pre-transplant. Eur J Haematol 71:73-80, 2003
30. Dreyling M, Lenz G, Hoster E, et al: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma: Results of a prospective randomized trial of the European MCL Network. Blood 105:2677-2684, 2005
31. Lefrere F, Delmer A, Suzan F, et al: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: A prospective study. Leukemia 16:587-593, 2002
32. Swann F Jr, Velasquez WS, Tucker S, et al: A new serologic staging system for large cell lymphoma based on initial beta-2 microglobulin and lactate dehydrogenase levels. J Clin Oncol 7:1518-1527, 1989
33. Litam P, Swan F, Cabanillas F, et al: Prognostic value of serum beta-2 microglobulin in low-grade lympnoma. Ann Intern Med 114:855-860, 1991
34. Armitage JO, Carbone PP, Connors JM, et al: Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol 21:897-906, 2003
35. Barista I, Cabanillas F, Romaguera JE, et al: Is there an increased rate of additional malignancies in patients with mantle cell lymphoma? Ann Oncol 13:318-322, 2002